Professional Documents
Culture Documents
Induction of Cyclooxygenase-2 by Epstein-Barr Virus
Induction of Cyclooxygenase-2 by Epstein-Barr Virus
Edited by Bernard Roizman, University of Chicago, Chicago, IL, and approved April 3, 2001 (received for review January 10, 2001)
Cyclooxygenase-2 (COX-2) is an inducible form of COX and is addition, EBV has been associated more recently with gastric
overexpressed in diverse tumors, raising the possibility of a role for carcinoma (10) and invasive breast cancer (11). In all of the
COX-2 in carcinogenesis. In addition, COX-2 contributes to angio- tumors, EBV infection is predominantly latent. EBV genes
genesis. The Epstein–Barr virus (EBV) oncoprotein, latent mem- expressed in latent infection are restricted to six EBV nuclear
brane protein 1 (LMP1), is detected in at least 70% of nasopha- antigens (EBNAs; EBNA1,-2, -3A, -3B, -3C, -LP) and three
MICROBIOLOGY
ryngeal carcinoma (NPC) and all EBV-infected preinvasive latent membrane proteins (LMPs; LMP1, -2A, -2B). According
nasopharyngeal lesions. We found that in specimens of LMP1- to the pattern of expression of those genes, EBV latent infection
positive NPC, COX-2 is frequently expressed, whereas LMP1- is divided into three groups. In type I latency, only EBNA1 is
negative NPC rarely express the enzyme. We next found that always expressed as represented by Burkitt’s lymphoma. In type
expression of LMP1 in EBV-negative nasopharyngeal epithelial III latency, all of the EBNAs and LMPs are expressed as in EBV
cells induced COX-2 expression. Coexpression of IB␣(S32A兾S36A), lymphoproliferative diseases in immunocompromised hosts. In
which is not phosphorylated and prevents NF-B activation, with type II latency, EBNA1 and the three LMPs are expressed as in
LMP1 showed that NF-B is essential for induction of COX-2 by NPC and in nasal T兾natural killer cell lymphoma. Among the
LMP1. We also demonstrate that NF-B is involved in LMP1-induced EBV latency genes, LMP1 is considered an oncoprotein because
cox-2 promoter activity with the use of reporter assays. Two major it can transform rodent fibroblasts (12). The carboxyl-terminal
regions of LMP1, designated CTAR1 and CTAR2, are signal-trans- portion of LMP1, which is in the cytoplasmic domain of the
ducing domains of LMP1. Constructs expressing either CTAR1 or protein, contains two functional domains. The proximal domain,
CTAR2 induce COX-2 but to a lesser extent than wild-type LMP1, COOH-terminal activation region (CTAR) 1, interacts with
consistent with the ability of both regions to activate NF-B. tumor necrosis factor receptor-associated factors and activates
Furthermore, we demonstrate that LMP1-induced COX-2 is func- NF-B (13, 14). The distal domain, CTAR2, interacts with tumor
tional because LMP1 increased production of prostaglandin E2 in a necrosis factor receptor-associated death domain protein and
COX-2-dependent manner. Finally, we demonstrate that LMP1 also activates NF-B (15). In addition to the activation of NF-B,
increased production of vascular endothelial growth factor (VEGF). LMP1 activates c-Jun NH2-terminal kinase through CTAR2 (16)
Treatment of LMP1-expressing cells with the COX-2-specific inhib- and also activates p38 mitogen-activated protein kinase through
itor (NS-398) dramatically decreased production of VEGF, suggest- both CTAR1 and CTAR2 (17).
ing that LMP1-induced VEGF production is mediated, at least in NPC is endemic in southern China and Taiwan, but it is rare
part, by COX-2. These results suggest that COX-2 induction by in the United States, Europe, and Japan. EBV genomes are
LMP1 may play a role in angiogenesis in NPC. detected in virtually all NPC worldwide and are monoclonal (18),
consistent with a causal role for NPC. LMP1 is detected in at
in 422F6 cells (Fig. 2A) and Ad-AH cells (Fig. 2B). Complete
abolition of LMP1-induced COX-2 expression by cotransfection
Fig. 2. NF-B is involved and essential for COX-2 induction by LMP1. Sup-
of IB␣(S32A兾S36A) was also observed in both HeLa (data not
pression of LMP1-induced COX-2 expression by IB␣(S32A兾S36A) is shown.
shown) and 293 cells (data not shown). Correspondingly, in- COX-2 expression was analyzed with or without coexpression of IB␣(S32A兾
creases in nuclear factor binding to NF-B binding sequence in S36A) (indicated as srIB) with LMP1 in 422F6 cells (A) or in Ad-AH cells (B) by
the cox-2 promoter in LMP1-expressing compared with vector- Western blotting. (C) Induction of nuclear factor binding to NF-B binding
transfected cells were demonstrated (Fig. 2C). In addition, sequence in the cox-2 promoter by LMP1 and its suppression by IB␣. Nuclear
cotransfection of IB␣(S32A兾S36A) abolished LMP1-induced extracts of 293 cells transfected as indicated were mixed with 32P-labeled
increases of nuclear factor binding to the NF-B binding se- NF-B probe and analyzed by electrophoretic mobility shift assay. An excess of
quence (Fig. 2C). nonlabeled NF-B (indicated as B) or NF-IL6 (indicated as IL6) probe (100⫻)
was used as competitor (NF-B, 5⬘-CAGGAGAGTGGGGACTACCCCCTCTGCT-3⬘;
NF-IL6, 5⬘-CACCGGGCTTACGCAATTTTTTTAA-3⬘). Underlined letters indicate
Both LMP1 CTAR1 and CTAR2 Induce COX-2 in Nasopharyngeal Epi- binding sequences in the promoter of the cox-2 gene. srIB, IB␣(S32A兾S36A);
thelial Cells. Two major regions of LMP1 are well known in the NS, nonspecific binding.
signal transduction induced by the oncoprotein: CTAR1 and
CTAR2. Therefore, we next investigated which LMP1 CTAR
plays a role in induction of COX-2 in nasopharyngeal epithelial induction, but to a lesser extent than in Ad-AH兾LMP1 cells;
cells. As shown in Fig. 3A, COX-2 was not induced in 422F6 cells however, induction was not observed in Ad-AH兾LMP1 1–187
by LMP1 1–187, which lacks both CTAR1 and CTAR2. On the cells (data not shown). Therefore, both CTAR1 and CTAR2
other hand, COX-2 was induced both by LMP1 1–231 and LMP1 seem to be needed for induction of COX-2.
⌬187–351, but to a lesser extent than by LMP1 wild type in 422F6
cells (Fig. 3A); the first construct contains only CTAR1 in the C NF-B Is Essential for Induction of COX-2 by Both CTAR1 and CTAR2 of
terminus; the second contains only CTAR2. Similarly, Ad-AH兾 LMP1. LMP1 has been shown to activate NF-B through both
LMP1 1–231 and Ad-AH兾LMP1 ⌬187–351 cells showed COX-2 CTAR1 and CTAR2. Therefore, we tested involvement of
LMP1 Induces the cox-2 Promoter in an NF-B-Dependent Manner. reducing conditions to dissociate dimer formation. VEGF pro-
Cox-2 promoter activity was analyzed by luciferase assays with duction in medium of LMP1-expressing 422F6 cells was in-
the constructs shown in Fig. 4A. As shown in Fig. 4B, LMP1 creased as shown in Fig. 6A. Because conditioned media were
induced cox-2 promoter activity. Coexpression of IB␣(S32A兾 analyzed, detected bands must be components of VEGF121 and
S36A) markedly, but not completely, repressed cox-2 promoter VEGF165, which are isoforms of secretory-type VEGF. Treat-
activity induced by LMP1 (Fig. 4B). Similarly, mutation in the ment of LMP1-expressing 422F6 cells with NS-398 clearly de-
NF-B binding site repressed LMP1-induced cox-2 promoter creased VEGF production (Fig. 6A), although COX-2 expres-
activation (Fig. 4B). sion was unaffected as shown in Fig. 5B. Expression of VEGF
induced by LMP1 was also clearly suppressed by IB␣(S32A兾
LMP1 Increases Prostaglandin E2 Production in Nasopharyngeal Epi- S36A) (Fig. 6 A). Enzymatic activity of matrix metal-
thelial Cells Through Induction of COX-2. We next tested whether loproteinase-2 (MMP-2) in each conditioned medium was un-
LMP1-induced COX-2 is functional. To this end, we measured changed in contrast to induction of MMP-9 in LMP1-expressing
production of PGE2 with EIA in 422F6 cells because PGE2 is one cells (Fig. 6B) as shown before (23, 29), which indicates that each
of the COX-2-mediated metabolic products of arachidonic acid. conditioned medium was obtained from an equal amount of
Fig. 5A shows that LMP1 markedly increased production of cells.
PGE2. To make certain that increased production of PGE2 is
through COX-2, we treated cells with the COX-2-specific inhib- Discussion
itor, NS-398, and showed that the inhibitor clearly decreased Recent studies have revealed that COX-2 is overexpressed in
LMP1-induced PGE2 as well as PMA-induced PGE2 production diverse tumors (1–6), suggesting that COX-2 may be involved in
(Fig. 5A). Because COX-2 expression induced by LMP1 and carcinogenesis. In fact, a selective COX-2 inhibitor reduced
PMA was not affected by NS-398 as shown in Fig. 5B, the tumorigenesis or tumor cell growth (30–32). NPC frequently
inhibitory effect of NS-398 on PGE2 production was not because expresses the EBV oncoprotein LMP1, prompting us to inves-
of the down-regulation of COX-2 expression. Coexpression of tigate whether LMP1 induces COX-2 in nasopharyngeal epithe-
IB␣(S32A兾S36A) with LMP1 dramatically decreased produc- lial cells. First, we showed that, with the use of Western blotting,
tion of PGE2 (Fig. 5A) because LMP1-induced COX-2 expres- LMP1-positive NPC frequently (but LMP1-negative LMP1
sion was inhibited by IB␣(S32A兾S36A) (Fig. 5B). rarely) expresses COX-2. Then, we showed that transient or
stable transfections clearly revealed that LMP1 induces COX-2
LMP1 Induces VEGF Production, at Least in Part, in a COX-2-Dependent in nasopharyngeal epithelial cells. A role for overexpression of
Manner. Finally, VEGF production in the conditioned medium COX-2 in various cancers is still unclear; however, the angio-
used in the experiment described in Fig. 5A was analyzed under genic role of COX-2 has been focused on recently. Angiogenesis
1. Sano, H., Kawahito, Y., Wilder, R. L., Hashiramoto, A., Mukai, S., Asai, K., 23. Yoshizaki, T., Sato, H., Furukawa, M. & Pagano, J. S. (1998) Proc. Natl. Acad.
Kimura, S., Kato, H., Kondo, M. & Hla, T. (1995) Cancer Res. 55, 3785–3789. Sci. USA 95, 3621–3626.
2. Wolff, H., Saukkonen, K., Anttila, S., Karjalainen, A., Vainio, H. & Ristimaki, 24. Miller, W. E., Mosialos, G., Kieff, E. & Raab-Traub, N. (1997) J. Virol. 71,
A. (1998) Cancer Res. 58, 4997–5001. 586–594.
3. Hwang, D., Scollard, D., Byrne, J. & Levine, E. (1998) J. Natl. Cancer Inst. 90, 25. Inoue, H., Nanayama, T., Hara, S., Yokoyama, C. & Tanabe, T. (1994) FEBS
455–460. Lett. 350, 51–54.
4. Ristimaki, A., Honkanen, N., Jankala, H., Sipponen, P. & Harkonen, M. (1997) 26. Inoue, H., Yokoyama, C., Hara, S., Tone, Y. & Tanabe, T. (1995) J. Biol. Chem.
Cancer Res. 57, 1276–1280. 270, 24965–24971.
5. Zimmermann, K. C., Sarbia, M., Weber, A. A., Borchard, F., Gabbert, H. E.
27. Inoue, H. & Tanabe, T. (1998) Biochem. Biophys. Res. Commun. 244, 143–148.
& Schror, K. (1999) Cancer Res. 59, 198–204.
28. Inoue, H., Umesono, K., Nishimori, T., Hirata, Y. & Tanabe, T. (1999)
6. Chan, G., Boyle, J. O., Yang, E. K., Zhang, F., Sacks, P. G., Shah, J. P.,
Biochem. Biophys. Res. Commun. 254, 292–298.
Edelstein, D., Soslow, R. A., Koki, A. T., Woerner, B. M., et al. (1999) Cancer
29. Murono, S., Yoshizaki, T., Sato, H., Takeshita, H., Furukawa, M. & Pagano,
Res. 59, 991–994.
7. Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M. & DuBois, R. N. (1998) J. S. (2000) Cancer Res. 60, 2555–2561.
Cell 93, 705–716. 30. Sheng, H., Shao, J., Kirkland, S. C., Isakson, P., Coffey, R. J., Morrow, J.,
8. Jones, M. K., Wang, H., Peskar, B. M., Levin, E., Itani, R. M., Sarfeh, I. J. & Beauchamp, R. D. & DuBois, R. N. (1997) J. Clin. Invest. 99, 2254–2259.
Tarnawski, A. S. (1999) Nat. Med. 5, 1418–1423. 31. Reddy, B. S., Hirose, Y., Lubet, R., Steele, V., Kelloff, G., Paulson, S., Seibert,
9. Sawaoka, H., Tsuji, S., Tsujii, M., Gunawan, E. S., Sasaki, Y., Kawano, S. & K. & Rao, C. V. (2000) Cancer Res. 60, 293–297.
Hori, M. (1999) Lab. Invest. 79, 1469–1477. 32. Rioux, N. & Castonguay, A. (1998) Cancer Res. 58, 5354–5360.
10. Shibata, D. & Weiss, L. M. (1992) Am. J. Pathol. 140, 769–774. 33. Folkman, J. (1992) Semin. Cancer Biol. 3, 65–71.
11. Bonnet, M., Guinebretiere, J. M., Kremmer, E., Grunewald, V., Benhamou, E., 34. Kim, Y. & Fischer, S. M. (1998) J. Biol. Chem. 273, 27686–27694.
Contesso, G. & Joab, I. (1999) J. Natl. Cancer Inst. 91, 1376–1381. 35. Yamamoto, K., Arakawa, T., Ueda, N. & Yamamoto, S. (1995) J. Biol. Chem.
12. Wang, D., Liebowitz, D. & Kieff, E. (1985) Cell 43, 831–840. 270, 31315–31320.
13. Mosialos, G., Birkenbach, M., Yalamanchili, R., VanArsdale, T., Ware, C. & 36. Coffey, R. J., Hawkey, C. J., Damstrup, L., Graves-Deal, R., Daniel, V. C.,
Kieff, E. (1995) Cell 80, 389–399. Dempsey, P. J., Chinery, R., Kirkland, S. C., DuBois, R. N., Jetton, T. L. &
14. Devergne, O., Hatzivassiliou, E., Izumi, K. M., Kaye, K. M., Kleijnen, M. F., Morrow, J. D. (1997) Proc. Natl. Acad. Sci. USA 94, 657–662.
Kieff, E. & Mosialos, G. (1996) Mol. Cell. Biol. 16, 7098–7108. 37. Miller, W. E., Earp, H. S. & Raab-Traub, N. (1995) J. Virol. 69, 4390–4398.
15. Izumi, K. M. & Kieff, E. D. (1997) Proc. Natl. Acad. Sci. USA 94, 12592–12597. 38. Gires, O., Zimber-Strobl, U., Gonnella, R., Ueffing, M., Marschall, G., Zeidler,
16. Kieser, A., Kilger, E., Gires, O., Ueffing, M., Kolch, W. & Hammerschmidt, W. R., Pich, D. & Hammerschmidt, W. (1997) EMBO J. 16, 6131–6140.
(1997) EMBO J. 16, 6478–6485.
39. Uchida, J., Yasui, T., Takaoka-Shichijo, Y., Muraoka, M., Kulwichit, W.,
17. Eliopoulos, A. G., Gallagher, N. J., Blake, S. M., Dawson, C. W. & Young, L. S.
Raab-Traub, N. & Kikutani, H. (1999) Science 286, 300–303.
(1999) J. Biol. Chem. 274, 16085–16096.
40. Maity, A., Pore, N., Lee, J., Solomon, D. & O’Rourke, D. M. (2000) Cancer Res.
18. Raab-Traub, N. & Flynn, K. (1986) Cell 47, 883–889.
19. Pathmanathan, R., Prasad, U., Sadler, R., Flynn, K. & Raab-Traub, N. (1995) 60, 5879–5886.
N. Engl. J. Med. 333, 693–698. 41. Yu, Y. & Chadee, K. (1998) J. Immunol. 161, 3746–3752.
20. Hu, L. F., Chen, F., Zhen, Q. F., Zhang, Y. W., Luo, Y., Zheng, X., Winberg, 42. Yoshida, S., Ono, M., Shono, T., Izumi, H., Ishibashi, T., Suzuki, H. & Kuwano,
G., Ernberg, I. & Klein, G. (1995) Eur. J. Cancer 5, 658–660. M. (1997) Mol. Cell. Biol. 17, 4015–4023.
21. Takimoto, T., Furukawa, M., Hatano, M. & Umeda, R. (1984) Ann. Otol. 43. Savard, M., Belanger, C., Tremblay, M. J., Dumais, N., Flamand, L., Borgeat,
Rhinol. Laryngol. 93, 166–169. P. & Gosselin, J. (2000) J. Immunol. 164, 6467–6473.
22. Takimoto, T., Kamide, M. & Umeda, R. (1984) Arch. Otorhinolaryngol. 239, 44. Horikawa, T., Yoshizaki, T., Sheen, T. S., Lee, S. Y. & Furukawa, M. (2000)
87–92. Cancer 89, 715–723.